Luminex Receives FDA EUA for ARIES SARS-CoV-2 Assay
India, April 7 -- US based Luminex Corporation hasannounced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its ARIES(R)SARS-CoV-2 Assay for rapid detection of the virus that causes COVID-19.
The assay runs on the ARIES(R)System, an FDA-cleared, sample-to-answer, automated, on-demand molecular diagnostic platform. The system is capable of running up to 144 tests per day, requiring no specialty training and minimal human interaction.
"The ARIES(R)SARS-CoV-2 Assay will allow hospital professionals to determine the appropriate course of treatment for patients suspected of having COVID-19 within approximately two hours," saidNachum "Homi" Shamir, President and CEO of Luminex. "We are grateful ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.